Activity Date: 04/21/2021
Migraine is common in children and adolescents with a prevalence of 8-23% by age 15 years and is associated with significant impact on academic performance, social functioning, peer/family relationships – particularly with recurrent, severe presentations. Association with anxiety and depressive disorders is common, warranting critical evaluation among both psychiatric and neurologic pharmacists. A variety of treatment strategies have been evaluated, including acute/preventive, behavioral/lifestyle, and complementary/alternative strategies. Recent updates in treatment guidelines, advancement in literature, and caregiver interest in complementary/alternative approaches make this a timely topic for psychiatric and neurologic pharmacists. The Child and Adolescent Psychiatry Community idea exchange will allow for high-level discussion of migraine treatment updates, clinical pearls, and perspectives from a neurologic pharmacist – allowing for much needed attention to this important topic. This will be a special opportunity to share tools, ideas, and current practices among this unique patient population.
Andrea Calvert, PharmD
Danielle Stutzman, PharmD, BCPP
Sandra Mullen, PharmD, BCPP
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
